Investments
166Portfolio Exits
30Funds
6Research containing Yunfeng Capital
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Yunfeng Capital in 4 CB Insights research briefs, most recently on Nov 10, 2021.
Latest Yunfeng Capital News
Jun 20, 2022
(Yicai Global) June 20 -- Chinese gene sequencing company Axbio has secured USD100 million in its latest financing round in which a medical industry fund run by UK pharmaceutical giant AstraZeneca and Chinese private equity firm CICC Capital took part. The medical fund joint venture together with Shanghai-based Yunfeng Capital led the B-series, venture capital news website Lieyunwang reported today. Other participants included Singaporean health-dedicated investment firm C-Bridge Capital. The new funding will allow Shenzhen-based Axbio to rapidly advance the development and commercialization of its new-generation sequencer in the fast-growing genomics market, a representative from C-Bridge Capital told Yicai Global. The firm’s first manufacturing facility in Wuxi, eastern Jiangsu province is due be completed by the end of the year, the person added. Axbio’s nanopore-based low-cost single-molecule sequencing platform is extremely important for the precision medicine market, said Marco Ma, managing director of a C-Bridge Capital subsidiary, CBC Venture. It enables fast cancer diagnostics, rapid pathogen detection and drug development. This is Axbio’s second fundraising round in nine months. In October last year, the company raised tens of millions of dollars in Series A+ financing led by several venture capital firms including Shanghai-based 5Y Capital. Editor: Kim Taylor
Yunfeng Capital Investments
166 Investments
Yunfeng Capital has made 166 investments. Their latest investment was in Axbio as part of their Series B on June 6, 2022.
Yunfeng Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/20/2022 | Series B | Axbio | $100M | Yes | 2 | |
6/14/2022 | Unattributed VC | Robosense | Yes | 2 | ||
2/17/2022 | Series C - II | Ruili | Yes | Alibaba Group, CCB Principal Capital Management, China Orient Asset Management, China Post Life Insurance, Genharmony Capital, Greater Bay Area Homeland Investments, Hexie Health Insurance, PICC Capital, Qianhai Fund of Funds, Shenzhen Investment Holdings, Sunshine Insurance Group, TCL Capital, Tencent Holdings, Walden International, and Waterwood Group | 1 | |
11/29/2021 | Series B | |||||
11/22/2021 | Series B - II |
Date | 6/20/2022 | 6/14/2022 | 2/17/2022 | 11/29/2021 | 11/22/2021 |
---|---|---|---|---|---|
Round | Series B | Unattributed VC | Series C - II | Series B | Series B - II |
Company | Axbio | Robosense | Ruili | ||
Amount | $100M | ||||
New? | Yes | Yes | Yes | ||
Co-Investors | Alibaba Group, CCB Principal Capital Management, China Orient Asset Management, China Post Life Insurance, Genharmony Capital, Greater Bay Area Homeland Investments, Hexie Health Insurance, PICC Capital, Qianhai Fund of Funds, Shenzhen Investment Holdings, Sunshine Insurance Group, TCL Capital, Tencent Holdings, Walden International, and Waterwood Group | ||||
Sources | 2 | 2 | 1 |
Yunfeng Capital Portfolio Exits
30 Portfolio Exits
Yunfeng Capital has 30 portfolio exits. Their latest portfolio exit was GemPharmatech on April 25, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/25/2022 | IPO | Public | 1 | ||
3/31/2022 | IPO - II | Public | 1 | ||
1/7/2022 | IPO | Public | 1 | ||
Date | 4/25/2022 | 3/31/2022 | 1/7/2022 | ||
---|---|---|---|---|---|
Exit | IPO | IPO - II | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | Public | ||
Sources | 1 | 1 | 1 |
Yunfeng Capital Acquisitions
11 Acquisitions
Yunfeng Capital acquired 11 companies. Their latest acquisition was Cellular Biomedicine Group on February 20, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
2/20/2021 | Series A | $120M | Take Private | 2 | ||
3/11/2019 | Acquired | 7 | ||||
1/18/2019 | Take Private | 8 | ||||
7/4/2018 | Other | |||||
12/8/2017 |
Date | 2/20/2021 | 3/11/2019 | 1/18/2019 | 7/4/2018 | 12/8/2017 |
---|---|---|---|---|---|
Investment Stage | Series A | Other | |||
Companies | |||||
Valuation | |||||
Total Funding | $120M | ||||
Note | Take Private | Acquired | Take Private | ||
Sources | 2 | 7 | 8 |
Yunfeng Capital Fund History
6 Fund Histories
Yunfeng Capital has 6 funds, including Yunfeng IK Co-invest.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
1/16/2019 | Yunfeng IK Co-invest | $50M | 3 | ||
8/3/2018 | Yunfeng Fund III | ||||
5/28/2014 | Yunfeng Fund II | ||||
12/31/2010 | Yunfeng Fund | ||||
Yunfeng Cloud Computing Fund |
Closing Date | 1/16/2019 | 8/3/2018 | 5/28/2014 | 12/31/2010 | |
---|---|---|---|---|---|
Fund | Yunfeng IK Co-invest | Yunfeng Fund III | Yunfeng Fund II | Yunfeng Fund | Yunfeng Cloud Computing Fund |
Fund Type | |||||
Status | |||||
Amount | $50M | ||||
Sources | 3 |
Yunfeng Capital Team
10 Team Members
Yunfeng Capital has 10 team members, including current Founding Partner, Jack Yun Y Ma.
Name | Work History | Title | Status |
---|---|---|---|
David Yu | Founder | Current | |
Jack Yun Y Ma | Founding Partner | Current | |
Yuzhu Shi | Founding Partner | Current | |
Yusuo Wang | Founding Partner | Current | |
Shiyao Guo | Managing Director | Current |
Name | David Yu | Jack Yun Y Ma | Yuzhu Shi | Yusuo Wang | Shiyao Guo |
---|---|---|---|---|---|
Work History | |||||
Title | Founder | Founding Partner | Founding Partner | Founding Partner | Managing Director |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.